Citation only
via OpenAlex
Synthesis and anticancer activity of novel rapamycin C‐28 containing triazole moiety compounds
Qingwen Huang, Lijun Xie, Xiaoming Chen, Hui Yu, Yubing Lv, XueHui Huang, Jiayin Ying, Congshen Zheng, Yuanrong Cheng, Jie Huang
Archiv der Pharmazie · 2018 · ▲ 9 citations
Deregulated nutrient-sensing
Altered intercellular communication
Rapamycin / mTOR inhibition
Cell culture / in vitro
Abstract
mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) is an mTOR allosteric inhibitor with multiple functions such as immunosuppressive, anticancer, and lifespan prolonging activities. Its C-43 semi-synthetic derivatives temsirolimus and everolimus have been used as mTOR targeting anticancer drugs in the clinic. Following our previous research on antitumor rapalogs modified on the C-43 position, 13 novel rapamycin triazole hybrids (6a-g, 7a-f) were designed and synthesized on the C-28 position of rapamycin via Huisgen's reaction. Anticancer assays indicated that the targeted derivatives containing phenyl and 4-methylphenyl groups showed an obvious raise in anticancer activity. On the contrary, the compounds with methoxyl, amine, and halogen groups on the benzene ring displayed lower anticancer activity. Compound 6c, as the most active compound, showed a stronger inhibition effect as compared with rapamycin for almost all of the tested cell lines (p < 0.01), except PC-3. Meanwhile, the effect of 6c on inducing apoptosis and cell cycle arrest in A549 cells was more powerful than that of rapamycin. In addition, 6c inhibited the phosphorylation of mTOR and its downstream key kinases 4EBP1 and p70S6K1 in A549 cells, indicating that 6c also effectively inhibits the mTORC1 signaling pathway as rapamycin. On the basis of these findings, 6c may have the potential to be developed as a new mTOR inhibitor against specific cancers.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ardp.201800123
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Huang, Q., Xie, L., Chen, X., Yu, H., Lv, Y., Huang, X., Ying, J., Zheng, C., Cheng, Y., & Huang, J. (2018). Synthesis and anticancer activity of novel rapamycin C‐28 containing triazole moiety compounds. <em>Archiv der Pharmazie</em>. https://doi.org/10.1002/ardp.201800123
Vancouver
Huang Q, Xie L, Chen X, Yu H, Lv Y, Huang X, et al. Synthesis and anticancer activity of novel rapamycin C‐28 containing triazole moiety compounds. Archiv der Pharmazie. 2018. doi:10.1002/ardp.201800123.
BibTeX
@article{qingwen2018Synthe,
title = {Synthesis and anticancer activity of novel rapamycin C‐28 containing triazole moiety compounds},
author = {Qingwen Huang and Lijun Xie and Xiaoming Chen and Hui Yu and Yubing Lv and XueHui Huang and Jiayin Ying and Congshen Zheng and Yuanrong Cheng and Jie Huang},
journal = {Archiv der Pharmazie},
year = {2018},
doi = {10.1002/ardp.201800123},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cancers 2022
Open access · CC-BY
Senolysis-Based Elimination of Chemotherapy-Induced Senescent Breast Cancer Cells by Quercetin Derivative with Blocked Hydroxy Groups
Cell Cycle 2018
Open access · CC-BY
Rapamycin, proliferation and geroconversion to senescence
JOR Spine 2020
Open access · CC-BY
Autophagy and mTOR signaling during intervertebral disc aging and degeneration
Accounts of Chemical Research 2024
Open access · CC-BY
Chemical Strategies for the Detection and Elimination of Senescent Cells
Frontiers in Aging 2021
Open access · CC-BY
The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging
IUScholarWorks (Indiana University) 2009
Preprint · OA